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The homeostatic balance between production and elimination of CD4+ T cells in
peripheral blood plays an important role in patients with neuromyelitis optica (NMO).
The objective of the present study was to evaluate the anti-apoptosis genes Bcl-2
and its promoter signal (nuclear factor kappa-light-chain-enhancer of activated B cells,
NFκB) in CD4+ T cells. Healthy subjects (HS, n = 25) and patients with multiple
sclerosis (MS) (n = 25) and NMO (n = 30) in remission were consecutively enrolled
in this prospective study between May and December 2015. CD4+ T cells were
isolated using magnetic beads coated with anti-CD4 monoclonal antibodies, and gene
expression of Bcl-2, NFκB, phosphatidylinositol-4, 5-bisphosphate 3-kinase/protein
kinase B (PI3K/Akt), and MAP kinase kinase kinase 7 (MAP3K7) was measured by
real-time reverse transcription-polymerase chain reaction (rt-PCR). Cytokines of tumor
necrosis factor (TNF)-α and interleukin (IL)-1β were detected using human cytokine
multiplex assay. Bcl-2 and NFκB gene expressions were elevated in NMO patients
(1.63 ± 0.25; 2.35 ± 0.25) compared with those of HS (0.90 ± 0.11; 1.42 ± 0.22)
and/or MS patients (1.03 ± 0.18; 1.55 ± 0.20) (P < 0.05). MAP3K7, but not Akt,
was increased in NMO patients (1.23 ± 0.18; 1.56 ± 0.22) (P < 0.01) and was a
significant factor related to elevated NFκB gene expressions (P < 0.001). On the other
hand, IL-1β and TNF-α were also detected in the study and the results showed that
both were elevated in NMO patients (23.84 ± 1.81; 56.40 ± 2.45) (P < 0.01; P <
0.05, respectively). We propose that MAP3K7 induced by IL-1β and TNF-α but not Akt
promotes NFκB expression and, in turn, prolongs Bcl-2–mediated survival of CD4+ T
cells in NMO patients.
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INTRODUCTION
Neuromyelitis optica (NMO) is an inflammatory disease
characterized by NMO immunoglobulin IgG (NMO-IgG), which
is primarily considered to be an AQP4-specific antibody in NMO
serum (Wingerchuk et al., 2015). Despite that B cells and auto-
antibodies play decisive pathogenic roles in NMO, several lines
of evidence suggest that T cells and cytokines have relevant
roles in NMO (Varrin-Doyer et al., 2012; Zeka et al., 2015).
Passive aquaporin (AQP) 4-IgG transfer alone does not produce
central nervous system (CNS) pathology, but does promote the
development of NMO-like lesions in recipient animals when
CNS inflammation is induced by myelin-specific T cells (Vaknin-
Dembinsky et al., 2012; Varrin-Doyer et al., 2012). This indicates
that AQP4-IgG–specific CD4+ T cells participates in the genesis
of NMO and that T cells appear to be equally crucial for the
full development of the immunopathogenetic cascade (Vaknin-
Dembinsky et al., 2012). Previous studies have identified the
myelin/MOG specific T cells to be CD4+ cells in spontaneous
CNS autoimmunity and NMO like diseases (Dasgupta and
Dasgupta, 2016; Klotz et al., 2016; Tostanoski et al., 2016). Once
the T cell is stimulated by agents such as TNF-α and IL-1β,
the phosphorylated MAP3K7 could phosphorylate IκB, which
has the ability to phosphorylate NFκB (DiDonato et al., 1997).
And, NFκB signals are required to promote the expression of
Bcl-2. Protein kinase B (Akt) was suggested in another study
to be an important driver of the glycolytic phenotype and is
linked to many cellular processes, including anti-apoptosis and
anti-autophagy (Majumder et al., 2004). Bcl-2 and its family
members have the ability to control apoptosis and anti-apoptosis
in balancing mitochondria permeability (the most common form
of programmed cell death in biology and disease; Hotchkiss et al.,
2009; Figure 1). In NMO and multiple sclerosis (MS) patients
and their animal models, subtypes of CD4+ T cells were elevated
compared to those of HS, and we found that one corollary of
these events is the lack of balance between apoptosis and anti-
apoptosis in CD4+ T cells (Uzawa et al., 2010; Wang et al., 2011).
This indicates that the homeostatic balance between production
and elimination of CD4+ T cells in peripheral blood plays a
special role in NMO. Even though a number of pathological or
physiological processes contributing to anti-apoptosis have been
described, limited understanding of anti-apoptosis in CD4+ T
cells in NMO hinders the development of an effective treatment.
CD4+ T cell subpopulations accumulate in peripheral blood
mononuclear cells (PBMCs) in NMO patients, implying anti-
apoptosis might be involved in pathogenesis. Bcl-2, which has
anti-apoptosis properties, was designed to value in this study. The
objective of the current study was to analyze the anti-apoptotic
factors in CD4+ T cells, such as Bcl-2 and its promoter signals,
in NMO patients during clinical remission.We also evaluated the
effects of cytokines on CD4+ T cell anti-apoptosis.
PATIENTS AND METHODS
Study Populations
Written informed consent was obtained from all subjects.
The current study protocol was approved by the local ethics
committee of Beijing Tiantan Hospital Affiliated with Capital
FIGURE 1 | MAP3K7 and PI3K/AKT pathways of NF-κB activation.
NF-κB activation occurs through many different pathways. Two of them are
MAP3K and PI3K/AKT. In both ways, activated MAP3K7 and PI3K/AKT
phosphorylate NF-κB, leading to IκB phosphorylation, ubiquitination and
proteosomal degradation. A NF-κB dimer is released and translocated into
nucleus, where it binds to the κB-binding site for upregulation of Bcl-2 gene
expression. Bcl-2 executes the function of anti-apoptosis.
Medical University China (No. KY2015-003-02). The study
population comprisedMS and NMO patients who were recruited
from Beijing Tiantan Hospital (age 16–60; all patients met
NMO or MS diagnosis; without other immune diseases; written
informed consent was obtained) and healthy subjects (HS) (age
16–60; without immune diseases) from the general population.
Infections were ruled out by full blood count in all subjects.
This study was conducted between May and December 2015
on 25 HS, 30 MS patients, and 30 NMO patients. The NMO
diagnosis was based on the revised diagnostic criteria (2006)
for NMO (Wingerchuk et al., 2006; the 2015 diagnostic criteria
had not been published when the study was carried out) and
the MS diagnosis was determined according to the 2010 revised
McDonald criteria (Polman et al., 2011).
CD4+ T Cells Collection
Peripheral blood were obtain at 9:00 a.m. using disposable
ethylenediaminetetraacetic acid (EDTA) vacuum blood
collection tubes (BD, USA), and PBMCs were collected by
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centrifugation on a Ficoll-Hypaque density gradient. The
purified CD4+ T cells were isolated using magnetic beads coated
with anti-CD4 monoclonal antibody (Miltenyi Biotec, Germany)
following the manufacturer’s instructions.
Quantitative Real-Time Polymerase Chain
Reaction (qRT-PCR)
Total RNA was isolated from approximately 50 to 100mg
purified CD4+ T cells using Trizol. The concentration of each
RNA sample wasmeasured spectrophotometrically. The integrity
of RNA samples was assessed by agarose gel electrophoresis.
The cDNA was synthesized using the PrimeScriptTM RT
reagent Kit with gDNA Eraser (1.0 µL) (TaKaRa bio, Japan).
The PCR primers were designed using Primer Premier 6.0
(http://www.premierbiosoft.com/primerdesign/) based on the
GenBank Accession codes and synthesized in Invitrogen (China).
Quantitative measurement of mRNA was performed using the
ABI Prism 7500 (Applied Biosystems, USA). These data were
analyzed using the comparative 2−11CT method (Livak and
Schmittgen, 2001).
Plasma Cytokines Levels
After standing for 2.0 h at 4.0◦C, the supernatant of
blood samples was pipetted into EP tubes and stored at
−80◦C. Plasma IL-1β and TNF-α were measured using
MILLIPLEX R© MAP Human High Sensitivity Cytokine Panels
(Cat. No. HCYTOMAG-60K) according to the manufacturer’s
instructions.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version
5 (GraphPad Software, Inc., California, USA) and the data
were reported as box and Whisker plots with the Whiskers
representing minimum and maximum values. Multi-group
comparisons of the means with one independent variable were
carried out by one-way analysis of variance (ANOVA) test with
post hoc contrasts by Student-Newman-Keuls test. The t-test was
used to compare 2 groups. Pearson’s test was used to perform
correlations. Power analysis was performed using G∗Power
(Version:3.1, Universität Regensburg, Berlin, German). A P <
0.05 was considered statistically significant.
RESULTS
We identified 25 HS, 25 MS patients, and 30 NMO patients
according to demographic and clinical data (Tables 1, 2). NMO
patients had more severe clinical neurological defects than MS
patients (P < 0.01) (Table 1).
We initially investigated the Bcl-2 and NFκB gene expressions
in the CD4+ T cells of HS, MS patients, and NMO patients.
Overexpression of anti-apoptotic member Bcl-2 in NMOpatients
conforms to the higher NFκB expression in those patients
(Figure 3A). NMO patients had higher expression of Bcl-2 gene
comparing with HS (P< 0.05). Even though the results indicated
NMO patients (mean = 1.63) had higher expression of Bcl-
2 than MS patients (mean = 1.03), there were non-significant
differences between the two (P = 0.06). The power analysis
suggested this result might be caused by the limited number of
TABLE 1 | Demographic and clinical data of healthy subjects (HS) and
multiple sclerosis (MS) and neuromyelitis optica (NMO) patients.
HS (n = 25) MS (n = 25) NMO (n = 30)
Gender F/M 18/7 18/7 25/5
Age (year) Range 16–54 16–53 13–55
Mean±SE 34.84 ± 2.24 33.48 ± 2.15 35.43 ± 2.28
Age at onset
(year)
Range – 6–51 11–53
Mean±SE – 29.60 ± 2.18 29.37 ± 2.14
Disease duration
(year)
Range – 0.25–11.92 0.17–21.50
Mean±SE – 3.91 ± 0.53 5.58 ± 0.87
ARR Range – 0.29–8.00 0.09–12.00
Mean±SE – 1.48 ± 0.32 1.69 ± 0.41
EDSS Range – 0–5.0 1–6.5
Mean±SE – 1.92 ± 1.39 3.07 ± 0.31**
HS, healthy subjects, MS, multiple sclerosis, NMO, neuromyelitis optica, EDSS, expanded
disability status scales; ARR, annual relapse rate. **P < 0.01.
recruiting members (setting parameter: n1 = 25, n2 = 30, results:
power = 0.46; Figure 2). And, suppose power = 0.8 and 0.5 are
satisfied, n = 62 and 31 in each group respectively. Given that
NFκB signals are required to promote the expression of Bcl-2
gene, we examined NFκB gene expression (Wang et al., 2015).
NMO patients had higher NFκB expression than HS and MS
patients (P < 0.05) (Figure 3B).
Phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) and
Akt genes were also tested in this study. Although PI3K and
Akt enhances Bcl-2 promoter activity by phosphorylating NFκB,
which is elevated in NMO patients, PI3K and Akt showed no
significant increase in NMO patients (P > 0.05) (Figures 4A,B).
Lacking differences in PI3K and Akt expressions in NMO
patients, MAP kinase kinase kinase 7 (MAP3K7), another
NFκB promoter, was measured. The results showed a significant
increase in the expression of MAP3K7 in NMO patients (vs. HS,
P < 0.05; vs. MS patients, P < 0.05) (Figure 4C).
Given that upregulating MAP3K could promote NFκB
gene expression, which, in turn, could enhance Bcl-2 gene
expression, the correlations between NFκB and Bcl-2 and
between MAP3K7 and NFκB were analyzed. Bcl-2 and NFκB
and NFκB and MAP3K7 had significant correlations among all
subjects (P = 0.0016, P < 0.0001, respectively; Figures 5A,B).
The cytokines TNF-α and IL-1β were detected in the
study. NMO patients have higher TNF-αlevels compared to HS
(P < 0.05) and NMO patients, and MS patients had higher levels
of IL-1β compared to HS (P < 0.01, P < 0.05, respectively;
Figures 6A,B).
DISCUSSION
Unlike MS patients, NMO patients have a more severe CNS
demyelinating syndrome characterized by bilateral simultaneous
neuritis and acute myelitis which is in accordance with the
Expanded Disability Status Scale we observed for these patients
(O’Connor et al., 1998; Huh et al., 2014; Wingerchuk et al., 2015).
Passive transfer of IgGs from NMO patients to experimental
autoimmune encephalomyelitis rats reduced the expression of
AQP4 in astrocytes coupling with severer clinical neurological
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TABLE 2 | Details of MS and NMO patients.
Patient No. Age (year)/ Disease dur Dur to the EDSS No. of
gender (month) last relapse relapse
MS-01 26/M 23 25 2.5 3
MS-02 53/M 51 20 2.5 3
MS-03 45/F 40 57 0 3
MS-04 33/F 30 33 1.5 3
MS-05 39/F 38 7 3 2
MS-06 32/M 27 59 0 3
MS-07 48/F 42 68 2.5 2
MS-08 18/F 14 44 3.5 2
MS-09 26/F 24 18 0 3
MS-10 49/F 45 48 2 2
MS-11 25/F 20 59 2.5 10
MS-12 24/M 21 39 0 4
MS-13 34/F 31 42 1 1
MS-14 16/F 14 21 1.5 6
MS-15 46/F 39 85 1 5
MS-16 25/M 23 22 3 2
MS-17 40/M 34 75 2 2
MS-18 42/F 41 16 2 3
MS-19 24/M 24 3 3.5 2
MS-20 42/F 39 43 3.5 5
MS-21 29/F 24 67 3 2
MS-22 34/F 31 34 2.5 1
MS-23 44/F 36 102 0 7
MS-24 26/F 23 44 5 2
MS-25 17/F 6 143 0 5
NMO-01 24/F 15 114 3 7
NMO-02 20/F 16 55 1.5 4
NMO-03 30/F 22 95 2 6
NMO-04 55/F 53 30 5.5 3
NMO-05 22/F 19 38 3.5 4
NMO-06 14/M 13 18 6.5 5
NMO-07 51/F 48 43 3 6
NMO-08 36/F 24 150 1.5 6
NMO-09 46/F 37 108 2.5 3
NMO-10 26/M 22 40 1 6
NMO-11 55/F 47 88 6.5 5
NMO-12 50/F 35 180 1.5 7
NMO-13 19/M 16 30 1.5 4
NMO-14 34/F 22 15 3.5 5
NMO-15 31/F 24 82 3.5 8
NMO-16 43/M 36 107 1 3
NMO-17 37/F 31 71 3.5 6
NMO-18 29/F 27 14 2 3
NMO-19 39/F 29 122 6 4
NMO-20 34/M 30 44 6 4
NMO-21 53/F 29 258 5.5 2
NMO-22 32/F 26 73 3 4
NMO-23 40/F 40 2 2.5 2
NMO-24 52/F 50 23 3 3
(Continued)
TABLE 2 | Continued
Patient No. Age (year)/ Disease dur Dur to the EDSS No. of
gender (month) last relapse relapse
NMO-25 48/F 45 13 2 2
NMO-26 24/F 20 46 3 4
NMO-27 38/F 31 83 3.5 5
NMO-28 23/F 21 23 1 3
NMO-29 13/F 11 15 1.5 6
NMO-30 45/F 42 29 2 4
No, number; F, female; M, male; EDSS, expanded disability status scales; Dur, duration.
functions (Bennett et al., 2009; Bradl et al., 2009). Conversely,
unimmunized rats with IgGs from NMO patients showed a
lack of pathology and neurological dysfunction, suggesting
that T cells, complements, and leukocytes participate in the
pathogenesis of AQP4-Ab–mediated pathology in NMO patients
(Chihara et al., 2011). Dysregulation in the cell death of
T cells leads to prolonged activation of autoreactive T cells
(Hagman et al., 2015). Bcl-2, which was originally identified
in follicular B-cell lymphomas and localized to the cytoplasmic
face of intracellular membranes (outer mitochondrial membrane,
endoplasmic reticulum), inhibits apoptosis (Marsden and
Strasser, 2003). Considering that the Bcl-2 has the ability to
prolong cell survival, CD4+ T cells can live longer in NMO
patients and might accumulate in peripheral blood to cause more
severe clinical features. In the current study, we analyzed Bcl-
2 gene expression in HS, MS patients, and NMO patients. We
found that Bcl-2 gene expression in CD4+ T cells of NMO
patients was higher than that in HS (P < 0.05). Based on the Bcl-
2-mediated dual purpose of inhibiting apoptosis and autophagy
(Sasi et al., 2009; Scarfò and Ghia, 2013), this accumulation of
CD4+T cells indicates that Bcl-2might play a critical role in anti-
apoptosis and anti-autophagy by modulating the permeability of
the mitochondria in NMO patients. This study showed Bcl-2
and its promoter signals as NFκB, MAP3K7, TNF-α, and IL-
1β were upregulated in CD4+ T cells during NMO remission.
Azathioprine-reduced Bcl-2 synthesis and release could lead
to mitochondrial dysfunction and cell death, as suggested an
effective treatment for NMO (Menor et al., 2004; Papadopoulos
et al., 2014).
In addition to Bcl-2 expression upregulated in NMO patients,
NFκB and its pathway were measured in this study. The
NFκB pathway plays an important role in inflammation,
immunity, apoptosis, and autophagy by regulating several
immunoregulatory factors (Verma and Manna, 2016). It is also
involved in both immune cell development and function, and is
critical in modulating immune response through transcriptional
regulation of cytokines and chemokines. The NFκB family of
transcription factors has been shown to regulate various aspects
of T cell development, activation, differentiation, and survival
(Oh and Ghosh, 2013). NFκB1 is one of the major targets of
the canonical pathway and the results in the current study
showed that NMO patients had higher NFκB 1 gene expression
compared with HS and MS patients (P < 0.05). Notably, Bcl-2
gene expression had a significant correlation with NFκB1 gene
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FIGURE 2 | Power analysis of Bcl-2 gene expressions between MS and NMO patients. Setting parameter: n1 = 25, n2 = 30, results: power = 0.46. n1:
number of MS patients; n2: number of NMO patients.
FIGURE 3 | Bcl-2 and NFκB genes expressions in CD4+ cells with HS, MS and NMO patients. (A) Comparison of Bcl-2 mRNA expression in CD4+ cells with
HS, MS and NMO patients. (B) Comparison of NFκB mRNA expression in CD4+ cells with HS, MS and NMO patients. HS = healthy subjects, MS = multiple
sclerosis, NMO = neuromyelitis optica. *P < 0.05.
FIGURE 4 | PI3K/Akt and MAP3K7 genes expressions in CD4+ cells with HS, MS and NMO patients. (A) Comparison of PI3K mRNA expression in CD4+
cells with HS, MS and NMO patients. (B) Comparison of Akt mRNA expression in CD4+ cells with HS, MS and NMO patients. (C) Comparison of MAP3K7 mRNA
expression in CD4+ cells with HS, MS and NMO patients. HS = healthy subjects, MS = multiple sclerosis, NMO = neuromyelitis optica. **P < 0.01.
expression in all test subjects (P = 0.0016). This illumined
NFκB1 pathway has an important role in increasing Bcl-2 gene
expression, in turn, to prolong the CD4+ T cells that might
participate in pathogenesis in NMO patients.
Other works have shown that activated PI3K and MAP3K7
results in phosphorylating Akt, which, in turn, upregulates Bcl-2
by enhancing Bcl-2 promoter activity (Pugazhenthi et al., 2000).
The current study showed that the PI3K/Akt pathway had not
changed in the NMO patients compared to that in MS patients
and HS, which indicated that the PI3K/Akt pathway might
not play a role in NMO pathogenesis (P > 0.05). Meanwhile,
MAP3K7 gene expression increased in NMO patients compared
to that in HS and MS patients (P < 0.01). To analyze whether
the expression of NFκB1 is associated with the conversion of
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FIGURE 5 | Correlation of gene expressions of all subjects. (A) Correlation between Bcl-2 and NFκB mRNA expressions in all subjects. (B) Correlation between
NFκB and MAP3K7 mRNA expressions in all subjects.
FIGURE 6 | Comparison of cytokine levels among HS, MS and NMO patients. (A) Comparison of plasma TNF-α levels among the HS, MS and NMO.
(B) Comparison of plasma IL-1β levels among the HS, MS and NMO. HS = healthy subjects, MS = multiple sclerosis, NMO = neuromyelitis optica. *P < 0.05, **P <
0.01, ***P < 0.001.
MAP3K7, the correlation among them was tested. The results
showed that MAP3K7 is strongly correlated with NFκB1 (P <
0.0001). This indicated that MAP3K7 has a decisive role in
upregulating NFκB1 rather than PI3K/Akt in NMO patients.
Usually, NFκB1 is sequestered in the cytoplasm of resting
cells by association with IκB family proteins (Karin and Ben-
Neriah, 2000). Once the cell is stimulated by agents such
as TNF-α and IL-1β, NFκB1 is activated through MAP3K7
phosphorylation (DiDonato et al., 1997). TNF-α and IL-1β have
the ability to transmit survival signals as Bcl-2 by activating
MAP3K7/NFκB1 transcription factors (Hagman et al., 2015). In
this study, both were evaluated in NMO patients (vs. HS, P <
0.001) and MS patients (vs. HS, P < 0.05). These factors, such
as Bcl-2, NFκB, MAP3K7, TNF-α, and IL-1β, somewhat inhibit
apoptosis of CD4+ T cells, which might then interact with B
cells and afford an opportunity to clinically relapse in NMO
patients.
Collectively, this study indicated that MAP3K7 expression is
stimulated by TNF-α and IL-1β and, in turn, activates NFκB
1, which has the ability to prolong Bcl-2-mediated CD4+ T
cell survival in NMO patients. The aberrant longevity of CD4+
T cells can lead to pathological immune cell accumulation in
NMO patients, which augments the risk of NMO relapse. These
results might help identify clinical applications for enhancing
the treatment of NMO; however, the study was not restricted to
subgroups of CD4+ T cells and, thus, we need to test which kinds
of CD4+T cells have aberrant Bcl-2 and its promotor expressions
in further studies, which might explain why MS patients have
elevated subtypes of CD4+ T cells but with relatively regular
Bcl-2 expression.
AUTHOR CONTRIBUTIONS
TY drafted this manuscript. TY, SW, and LW performed
the MILLIPLEX R© MAP Human High Sensitivity
Cytokine/Chemokine Panels tests, performed the real-time
rtPCR, and participated in collecting samples. LW, XY, QZ, QL,
MW, and ZD performed the statistical analysis and evaluated
the EDSS scores of patients. TY, SW, and YF participated in the
design and coordination of the study. TY conceived of the study
and participated in its design. LW revised the manuscript. All
authors read and approved the final manuscript.
Frontiers in Neuroscience | www.frontiersin.org 6 January 2017 | Volume 11 | Article 11
Yang et al. Upregulation of Bcl-2 in NMO
ACKNOWLEDGMENTS
YF and LW were responsible for accessing the following
research funds: National Natural Science Foundation of
China (CN) (81072765, 81173237, 81473640), the Program of
Changcheng Scholars for the Importation and Development of
High-Caliber Talents Project of Beijing Municipal Institutions
(CIT&TCD20140329), and the Beijing Natural Science
Foundation (7142053).
REFERENCES
Bennett, J. L., Lam, C., Kalluri, S. R., Saikali, P., Bautista, K., Dupree, C.,
et al. (2009). Intrathecal pathogenic anti-aquaporin-4 antibodies in early
neuromyelitis optica. Ann. Neurol. 66, 617–629. doi: 10.1002/ana.21802
Bradl, M., Misu, T., Takahashi, T., Watanabe, M., Mader, S., Reindl, M., et al.
(2009). Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
Ann. Neurol. 66, 630–643. doi: 10.1002/ana.21837
Chihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T.,
et al. (2011). Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody
production from plasmablasts in neuromyelitis optica. Proc. Natl. Acad. Sci.
U.S.A. 108, 3701–3706. doi: 10.1073/pnas.1017385108
Dasgupta, S., and Dasgupta, S. (2016). Antigen presentation for priming
T cells in central system. Int. J. Biochem. Cell Biol. 82, 41–48.
doi: 10.1016/j.biocel.2016.11.015
DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997).
A cytokine-responsive IkappaB kinase that activates the transcription factor
NF-kappaB. Nature 388, 548–554. doi: 10.1038/41493
Hagman, S., Kolasa, M., Basnyat, P., Helminen, M., Kahonen, M., Dastidar,
P., et al. (2015). Analysis of apoptosis-related genes in patients with
clinically isolated syndrome and their association with conversion to
multiple sclerosis. J. Neuroimmunol. 280, 43–48. doi: 10.1016/j.jneuroim.2015.
02.006
Hotchkiss, R. S., Strasser, A., McDunn, J. E., and Swanson, P. E. (2009). Cell death.
N.Engl. J. Med. 361, 1570–1583. doi: 10.1056/NEJMra0901217
Huh, S. Y., Kim, S. H., Hyun, J.W., Joung, A. R., Park, M. S., Kim, B. J., et al. (2014).
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum
disorder. JAMA Neurol. 71, 1372–1378. doi: 10.1001/jamaneurol.2014.2057
Karin, M., and Ben-Neriah, Y. (2000). Phosphorylation meets ubiquitination:
the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18, 621–663.
doi: 10.1146/annurev.immunol.18.1.621
Klotz, L., Kuzmanov, I., Hucke, S., Gross, C. C., Posevitz, V., Dreykluft, A., et al.
(2016). B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and
regional encephalitogenicity in spontaneous CNS autoimmunity. Proc. Natl.
Acad. Sci. U.S.A. 113, E6182–E6182. doi: 10.1073/pnas.1601350113
Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25, 402–408. doi: 10.1006/meth.2001.1262
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M.,
et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial
neoplasia through regulation of apoptotic andHIF-1-dependent pathways.Nat.
Med. 10, 594–601. doi: 10.1038/nm1052
Marsden, V. S., and Strasser, A. (2003). Control of apoptosis in the
immune system: Bcl-2, BH3-only proteins and more. Annu. Rev.
Immunol. 21, 71–105. doi: 10.1146/annurev.immunol.21.120601.
141029
Menor, C., Fernández-Moreno, M. D., Fueyo, J. A., Escribano, O., Olleros,
T., Arriaza, E., et al. (2004). Azathioprine acts upon rat hepatocyte
mitochondria and stress-activated protein kinases leading to necrosis:
protective role of N-acetyl-L-cysteine. J. Pharmacol. Exp. Ther. 311, 668–676.
doi: 10.1124/jpet.104.069286
O’Connor, P., Marchetti, P., Lee, L., and Perera, M. (1998). Evoked
potential abnormality scores are a useful measure of disease burden
in relapsing-remitting multiple sclerosis. Ann. Neurol. 44, 404–407.
doi: 10.1002/ana.410440320
Oh, H., andGhosh, S. (2013). NF-kappaB: roles and regulation in different CD4(+)
T-cell subsets. Immunol. Rev. 252, 41–51. doi: 10.1111/imr.12033
Papadopoulos, M. C., Bennett, J. L., and Verkman, A. S. (2014).
Treatment of neuromyelitis optica: state-of-the-art and emerging
therapies. Nat. Rev. Neurol. 10, 493–506. doi: 10.1038/nrneurol.
2014.141
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M.,
et al. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the
McDonald criteria. Ann. Neurol. 69, 292–302. doi: 10.1002/ana.22366
Pugazhenthi, S., Nesterova, A., Sable, C., Heidenreich, K. A., Boxer, L. M., Heasley,
L. E., et al. (2000). Akt/protein kinase B up-regulates Bcl-2 expression through
cAMP-response element-binding protein. J. Biol. Chem. 275, 10761–10766.
doi: 10.1074/jbc.275.15.10761
Sasi, N., Hwang, M., Jaboin, J., Csiki, I., and Lu, B. (2009). Regulated cell death
pathways: new twists inmodulation of BCL2 family function.Mol. Cancer Ther.
8, 1421–1429. doi: 10.1158/1535-7163.MCT-08-0895
Scarfò, L., and Ghia, P. (2013). Reprogramming cell death: BCL2 family
inhibition in hematological malignancies. Immunol. Lett. 155, 36–39.
doi: 10.1016/j.imlet.2013.09.015
Tostanoski, L. H., Chiu, Y. C., Gammon, J. M., Simon, T., Andorko, J. I., Bromberg,
J. S., et al. (2016). Reprogramming the local lymph node microenvironment
promotes tolerance that is systemic and antigen specific. Cell Rep. 16,
2940–2952. doi: 10.1016/j.celrep.2016.08.033
Uzawa, A., Mori, M., Arai, K., Sato, Y., Hayakawa, S., Masuda, S., et al. (2010).
Cytokine and chemokine profiles in neuromyelitis optica: significance of
interleukin-6.Mult. Scler. 16, 1443–1452. doi: 10.1177/1352458510379247
Vaknin-Dembinsky, A., Brill, L., Kassis, I., Petrou, P., Ovadia, H., Ben-Hur, T., et al.
(2012). T-cell reactivity against AQP4 in neuromyelitis optica. Neurology 79,
945–946. doi: 10.1212/WNL.0b013e318266fc2b
Varrin-Doyer, M., Spencer, C. M., Schulze-Topphoff, U., Nelson, P. A., Stroud,
R. M., Cree, B. A., et al. (2012). Aquaporin 4-specific T cells in neuromyelitis
optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann.
Neurol. 72, 53–64. doi: 10.1002/ana.23651
Verma, N., and Manna, S. K. (2016). Advanced glycation end products
(AGE) potently induce autophagy through activation of RAF protein
kinase and nuclear factor κB (NF-κB). J. Biol. Chem. 291, 1481–1491.
doi: 10.1074/jbc.M115.667576
Wang, H. H., Dai, Y. Q., Qiu, W., Lu, Z. Q., Peng, F. H., Wang, Y. G., et al. (2011).
Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis
during relapse. J. Clin. Neurosci. 18, 1313–1317. doi: 10.1016/j.jocn.2011.01.031
Wang, Y., Wang, R., Wang, Y., Peng, R., Wu, Y., and Yuan, Y. (2015). Ginkgo
biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK,
NF-κB/IκBα, and Bcl-2/Bax signaling. Drug Des. Devel. Ther. 9, 6303–6317.
doi: 10.2147/DDDT.S93732
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W.,
Chitnis, T., et al. (2015). International consensus diagnostic criteria
for neuromyelitis optica spectrum disorders. Neurology 85, 177–189.
doi: 10.1212/WNL.0000000000001729
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., and
Weinshenker, B. G. (2006). Revised diagnostic criteria for neuromyelitis optica.
Neurology 66, 1485–1489. doi: 10.1212/01.wnl.0000216139.44259.74
Zeka, B., Hastermann, M., Hochmeister, S., Kögl, N., Kaufmann, N., Schanda, K.,
et al. (2015). Highly encephalitogenic aquaporin 4-specific T cells and NMO-
IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta.
Neuropathol. 130, 783–798. doi: 10.1007/s00401-015-1501-5
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Yang, Wang, Yang, Zheng, Wang, Li, Wei, Du and Fan. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neuroscience | www.frontiersin.org 7 January 2017 | Volume 11 | Article 11
